Table 2. Thrombophilic risk factors (TRFs) examined in this study.

	Prevalence of TRFs in this study population: total number /associated with a further TRF given as number of patients (percentage)	Prevalence in the general population (Europe)	Estimated increased thrombotic risk in the general population[2, 22–24]
Factor V Leiden (G1691A)	10/7 (14.0/10.0%)	3–7%	3–5× (heterozygous)
Factor II (prothrombin) (G20120A)	4/2 (5.7/2.9%)	1–3%	3–7× (heterozygous)
Antithrombin III deficiency	9/6 (12.9/8.6%)	0.03–0.3%*	5–15×
Protein S deficiency	4/2 (5.7/2.9%)	0.2–1%	2–3×
Protein C deficiency	2/2 (2.9/2.9%)	0.2–0.5%	5–8×
MTHFR (C677CT)	32[2]/14 [0](45.7/20.0%) [homozygous]	30–40% (heterozygous)	2–3× viahomocystein ⇑
		15% (homozygous)
Antiphospholipid antibodies	14/11 (20/15.7%)
- Lupus coagulant (LC)	7/6 (10/8.6%)	2–3%	10×
- Anti-cardiolipin (AC)	6/5 (8.6/7.1%)	1–2%	1.5×
- LC and AC	1/0 (1.4/0%)

Data estimating the prevalence and thrombotic risk are derived from various studies. For details see the text. *hereditary forms